Positions
- Director
-
Center for NextGen Therapeutics
草榴社区入口
Houston, Texas United States
- Michael E. DeBakey, M.D., Professor in Pharmacology
-
Biochemistry and Molecular Pharmacology
草榴社区入口
Houston, Texas United States
- Professor
-
Molecular and Cellular Biology
草榴社区入口
Houston, Texas United States
- Member
-
Dan L Duncan Comprehensive Cancer Center
草榴社区入口
Houston, Texas United States
Addresses
- 1 Baylor Plaza (Office)
-
Room: Alkek N520.05
Houston, TX 77030
United States
Education
- BS from Peking University
- 07/2003 - Beijing, China
- Chemistry
- PhD from The Ohio State University
- 12/2007 - Columbus, Ohio United States
- Organic Chemistry
- Postdoctoral Training at University of North Carolina at Chapel Hill
- 05/2011 - Chapel Hill, North Carolina United States
- Drug Delivery and Nanomedicine
Honors & Awards
- Michael E. DeBakey, M.D., Professorship in Pharmacology
- 草榴社区入口 (06/2021)
- Teaching Award - Outstanding Lecturer
- 草榴社区入口 Graduate School (12/2020)
- Teaching Award - Chemical Biology as the Best Course in the CPSB Program
- 草榴社区入口 Graduate School (12/2020)
- Distinguished Faculty Award
- Chinese American Chemistry & Chemical Biology Professors Association (CAPA) (12/2020)
- CPRIT Scholar in Cancer Research
- Cancer Prevention and Research Institute of Texas (CPRIT) (07/2011)
Professional Interests
- Chemical Biology
- Sensors and Probes
- Small Molecule Drug Discovery
- Proteolysis-Targeting Chimeras (PROTACs), Targeted Protein Degradation (TPD)
- Antibody Drug Conjugates (ADCs)
- Proteomics and Chemoproteomics
- Cancer Immunotherapies
- Auto-inflammatory and auto-immune diseases
- Neurodegenerative diseases, such as Alzheimer's disease (AD)
- Metabolic diseases, such as obesity
Professional Statement
At 草榴社区入口 (BCM), my research harnesses the power of chemistry to address fundamental questions in biology and drive therapeutic innovation. We function as a highly integrated academic drug discovery unit, mirroring many capabilities of a biotech setting. Our expertise covers the spectrum from target identification and validation to preclinical testing, including artificial intelligence (AI) and physics-based computational modeling (folding, docking, MD simulations), medicinal chemistry, structural biology, biochemical and cell-based assay development, in-house DMPK profiling, and evaluation in animal models. This comprehensive approach allows us to rationally design diverse therapeutic modalities like small molecule inhibitors, protein degraders (PROTACs, molecular glues), and antibody-drug conjugates, as well as novel chemical biology tools. Notable achievements include developing the widely adopted quantitative GSH fluorescent probe, pioneering SI-2 inhibitors against the challenging SRC-3 oncoprotein, and creating a novel brain-penetrant sEH inhibitor for Alzheimer's disease. Currently, we are intensely focused on advancing targeted protein degradation strategies and employing chemoproteomics to identify novel covalent inhibitors, ultimately aiming to translate our discoveries into improved human health outcomes.Websites
VIICTR Research Database
Selected Publications
- Xin Yu, Dong Lu, Xiaoli Qi, Rishi Ram Paudel, Hanfeng Lin, Bryan L Holloman, Feng Jin, Longyong Xu, Lang Ding, Weiyi Peng, Meng C Wang, Xi Chen, Jin Wang "." Nature Communications. 2024 Dec 16;15(1):1-14. Pubmed PMID:
- Lingfei Wang, Hanfeng Lin, Bin Yang, Xiqian Jiang, Jianwei Chen, Sandipan Roy Chowdhury, Ninghui Cheng, Paul A Nakata, David M Lonard, Meng C Wang, Jin Wang "." J. Am. Chem. Soc. 2024 Jul 30;146(32):22396-22404. Pubmed PMID:
- Wen-Hao Guo, Xiaoli Qi, Yang Liu, Chan-I Chung, Fang Bai, Xingcheng Lin, Lingfei Wang, Jianwei Chen, Krystle J. Nomie, Feng Li, Meng C. Wang, Xiaokun Shu, Jos茅 N. Onuchic, Jennifer A. Woyach, Michael L. Wang, Jin Wang* "." Nature Communications. 2020;11:4268. Pubmed PMID:
- Jiang X, Chen J, Baji膰 A, Zhang C, Song X, Carroll SL, Cai ZL, Tang M, Xue M, Cheng N, Schaaf CP, Li F, MacKenzie KR, Ferreon ACM, Xia F, Wang MC, Maleti膰-Savati膰 M, Wang J "." Nature Communications. 2017 Jul 13;8:16087. Pubmed PMID:
- Song X, Chen J, Zhao M, Zhang C, Yu Y, Lonard DM, Chow DC, Palzkill T, Xu J, O'Malley BW, Wang J. "." Proc Natl Acad Sci USA. 2016 May 3;113(18):4970-5. Pubmed PMID:
- Dong Lu, Xin Yu, Hanfeng Lin, Ran Cheng, Erika Y Monroy, Xiaoli Qi, Meng C Wang, Jin Wang "." Chem. Soc. Rev.. 2022 May 9;51(22):9243-9261. Pubmed PMID:
- Xin Yu, Hanfeng Lin, Feng Li, Jin Wang, Dong Lu "." ACS Med Chem Lett. 2024 May 10;15(6) Pubmed PMID:
- Xin Yu, Wen-Hao Guo, Hanfeng Lin, Ran Cheng, Erika Y Monroy, Feng Jin, Lang Ding, Dong Lu, Xiaoli Qi, Meng C Wang, Jin Wang "." 2022 May 17;2:100029. Pubmed PMID:
- Hanfeng Lin, Kristin Riching, May Poh Lai, Dong Lu, Ran Cheng, Xiaoli Qi, Jin Wang "." ACS Med Chem Lett. 2024 Jul 28;15(8):1367-1375. Pubmed PMID:
- Harmon Greenway, Jin Wang "." ACS Med Chem Lett. 2024 Aug 30;15(9):1598-1605. Pubmed PMID:
- Dong Lu, Jianwei Chen, Li Qin, Imani Bijou, Ping Yi, Feng Li, Xianzhou Song, Kevin R MacKenzie, Xin Yu, Bin Yang, Sandipan Roy Chowdhury, James D Korp, Bert W O鈥橫alley, David M Lonard, Jin Wang "." J. Med. Chem.. 2024 Mar 29;67(7):5333-5350. Pubmed PMID:
Funding
- Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies - #1R01CA268518-01 (06/01/2022 - 05/31/2027) Grant funding from NIH/NCI
- RIP PROTACs as a Novel Immunotherapy Sensitizer to Treat Colorectal Cancer - #RP220480 (03/01/2022 - 02/28/2025) Grant funding from CPRIT
- Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease - #U01AG068031 (09/15/2020 - 05/31/2025) Grant funding from NIH/NIA
- Reversible Covalent BTK Degraders As the Next Generation Targeted Therapy To Treat B-Cell Malignancies - #R01CA250503 (07/01/2020 - 06/30/2025) Grant funding from NIH/NCI
- TARGETING A LIPID-MEDIATED PRO-LONGEVITY PATHWAY AS ALZHEIMER'S THERAPY - #RF1AG062257 (09/15/2018 - 06/30/2023) Grant funding from NIH/NIA
- Drugging the Undruggable Coactivators using Small Molecule Inhibitors - #R01CA207701 (03/15/2017 - 02/28/2022) Grant funding from NIH/NCI
- Real-Time Quantitative Imaging of Intracellular Biothiol Dynamics - #R01GM115622 (09/22/2015 - 07/31/2021) Grant funding from NIH/NIGMS
- Engineering Antibody Drug Conjugates to Target P53-Defective Triple Negative Breast Cancer - #R21CA213535 (06/13/2017 - 05/31/2019) Grant funding from NIH/NCI
Intellectual Property
- Product Patent (Pending)
- Co Inventors: Xiqian Jiang; Jianwei Chen
- Product Patent (Approved)
- Co Inventors: Fude Feng
- Product Patent (Approved)
- Co Inventors: Bert W. O鈥橫alley, David M. Lonard, Jianming Xu, and Jianwei Chen
- Product Patent (Pending)
- Co Inventors: Jin Wang, Wen-Hao Guo, Xiaoli Qi, Michael Wang, Krystle Nomie, and Yang Yu
- Product Patent (Pending)
- Co Inventors: Jin Wang, Hui Zheng, Lisheng Deng, and Anamitra Ghosh
to edit your profile
